BFA
KPRX icon

BlackRock Fund Advisors’s Kiora Pharmaceuticals KPRX Stock Holding History

BlackRock Fund Advisors’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$17K Hold
2
– – ﹤0.01% 3900
2016
Q3 		$18K Hold
2
– – ﹤0.01% 3885
2016
Q2 		$27K Buy
+2
New +$34.8K ﹤0.01% 3880

Other funds holding KPRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock Fund Advisors's KPRX Position: Q4 2016 in Review

BlackRock Fund Advisors held its Kiora Pharmaceuticals (KPRX) position steady in Q4 2016 at 2 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #3900.

BlackRock Fund Advisors first reported a position in KPRX in Q2 2016 and has held it in 3 quarters since. The position peaked at $27K in Q2 2016. 5 funds tracked by Wall St. Rank hold KPRX as of Q4 2016.

  • BlackRock Fund Advisors held 2 shares of Kiora Pharmaceuticals worth $17K as of Q4 2016.
  • BlackRock Fund Advisors left its Kiora Pharmaceuticals share count unchanged in Q4 2016.
  • Kiora Pharmaceuticals made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3900 holding.
  • BlackRock Fund Advisors first reported a position in Kiora Pharmaceuticals in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Fund Advisors's Kiora Pharmaceuticals position peaked at $27K in Q2 2016.
  • 5 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.